Allspring Global Investments Holdings LLC Has $40.02 Million Stock Position in Ascendis Pharma A/S $ASND

Allspring Global Investments Holdings LLC lessened its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 2.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 187,642 shares of the biotechnology company’s stock after selling 4,030 shares during the quarter. Allspring Global Investments Holdings LLC owned approximately 0.30% of Ascendis Pharma A/S worth $40,022,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the stock. Advisory Services Network LLC bought a new stake in Ascendis Pharma A/S during the 3rd quarter valued at approximately $26,000. Jones Financial Companies Lllp increased its holdings in shares of Ascendis Pharma A/S by 57.2% in the third quarter. Jones Financial Companies Lllp now owns 228 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 83 shares in the last quarter. Quadrant Capital Group LLC bought a new position in Ascendis Pharma A/S in the third quarter valued at about $74,000. Farther Finance Advisors LLC raised its position in shares of Ascendis Pharma A/S by 115.3% during the 3rd quarter. Farther Finance Advisors LLC now owns 478 shares of the biotechnology company’s stock valued at $95,000 after acquiring an additional 256 shares during the last quarter. Finally, Toth Financial Advisory Corp increased its stake in Ascendis Pharma A/S by 33.7% in the third quarter. Toth Financial Advisory Corp now owns 595 shares of the biotechnology company’s stock valued at $118,000 after purchasing an additional 150 shares in the last quarter.

Ascendis Pharma A/S Price Performance

NASDAQ ASND opened at $229.25 on Friday. Ascendis Pharma A/S has a one year low of $124.06 and a one year high of $248.60. The business’s fifty day moving average is $227.29 and its 200-day moving average is $213.55. The stock has a market capitalization of $14.29 billion, a price-to-earnings ratio of -52.10 and a beta of 0.49.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings results on Thursday, February 12th. The biotechnology company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.58). The company had revenue of $290.38 million for the quarter, compared to the consensus estimate of $285.35 million. Research analysts expect that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Wolfe Research reaffirmed an “outperform” rating and issued a $260.00 target price on shares of Ascendis Pharma A/S in a research note on Monday, March 2nd. Oppenheimer lifted their price target on shares of Ascendis Pharma A/S from $246.00 to $262.00 and gave the company an “outperform” rating in a research report on Thursday, February 12th. Stifel Nicolaus set a $332.00 target price on Ascendis Pharma A/S in a research note on Wednesday, March 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Ascendis Pharma A/S in a report on Wednesday, January 21st. Finally, Barclays initiated coverage on shares of Ascendis Pharma A/S in a report on Tuesday, January 27th. They issued an “overweight” rating and a $342.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Ascendis Pharma A/S presently has an average rating of “Moderate Buy” and a consensus price target of $289.89.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.